Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CRPPA Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
CRPPA Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CRPPA, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
CRMP1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
CRMP1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CRMP1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
Nephropathic cystinosis Indication Strategy Report 2026: CTNS, Trials and Deals
Latest Hotspot
8 min read
Nephropathic cystinosis Indication Strategy Report 2026: CTNS, Trials and Deals
21 July 2026
Nephropathic cystinosis indication strategy report covering epidemiology, CTNS biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Autosomal recessive polycystic kidney disease Indication Strategy Report 2026: PKHD1, Trials and Deals
Latest Hotspot
8 min read
Autosomal recessive polycystic kidney disease Indication Strategy Report 2026: PKHD1, Trials and Deals
21 July 2026
Autosomal recessive polycystic kidney disease indication strategy report covering epidemiology, PKHD1 biology, active trials, competition and deal signals using...
Read →
Hepatorenal syndrome Indication Strategy Report 2026: AVPR1A, Trials and Deals
Latest Hotspot
8 min read
Hepatorenal syndrome Indication Strategy Report 2026: AVPR1A, Trials and Deals
21 July 2026
Hepatorenal syndrome indication strategy report covering epidemiology, AVPR1A biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Acute kidney injury Indication Strategy Report 2026: TIM1, Trials and Deals
Latest Hotspot
8 min read
Acute kidney injury Indication Strategy Report 2026: TIM1, Trials and Deals
21 July 2026
Acute kidney injury indication strategy report covering epidemiology, TIM1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Nephrotic syndrome Indication Strategy Report 2026: CD80, Trials and Deals
Latest Hotspot
8 min read
Nephrotic syndrome Indication Strategy Report 2026: CD80, Trials and Deals
21 July 2026
Nephrotic syndrome indication strategy report covering epidemiology, CD80 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
IgA vasculitis nephritis Indication Strategy Report 2026: BAFF, Trials and Deals
Latest Hotspot
8 min read
IgA vasculitis nephritis Indication Strategy Report 2026: BAFF, Trials and Deals
21 July 2026
IgA vasculitis nephritis indication strategy report covering epidemiology, BAFF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
C3 glomerulopathy Indication Strategy Report 2026: C3, Trials and Deals
Latest Hotspot
8 min read
C3 glomerulopathy Indication Strategy Report 2026: C3, Trials and Deals
21 July 2026
C3 glomerulopathy indication strategy report covering epidemiology, C3 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Focal segmental glomerulosclerosis Indication Strategy Report 2026: TRPC5, Trials and Deals
Latest Hotspot
8 min read
Focal segmental glomerulosclerosis Indication Strategy Report 2026: TRPC5, Trials and Deals
21 July 2026
Focal segmental glomerulosclerosis indication strategy report covering epidemiology, TRPC5 biology, active trials, competition and deal signals using PatSnap MCP...
Read →
APOL1-mediated kidney disease Indication Strategy Report 2026: APOL1, Trials and Whitespace
Latest Hotspot
8 min read
APOL1-mediated kidney disease Indication Strategy Report 2026: APOL1, Trials and Whitespace
21 July 2026
APOL1-mediated kidney disease indication strategy report covering epidemiology, APOL1 biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Pulmonary hypertension due to left heart disease Indication Strategy Report 2026: PDE5A, Trials and Deals
Latest Hotspot
8 min read
Pulmonary hypertension due to left heart disease Indication Strategy Report 2026: PDE5A, Trials and Deals
21 July 2026
Pulmonary hypertension due to left heart disease indication strategy report covering epidemiology, PDE5A biology, active trials, competition and deal signals...
Read →